CyFlow™ CD20 APC

CyFlow™ CD20 APC
Laser: Red
Target Species: Human, Non-Human Primates
Antigen: CD20
Field of Interest: Immunophenotyping, Signaling
Clone: 2H7
Regulatory Status: RUO
Alternative Name: B1, Bp35
Application: Flow cytometry
Format/Fluorochrome: APC
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 660 nm
Excitation Maximum: 650 nm
Isotype: IgG2b
Product number: BS173993

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA IV—WS Code B201 Quantity 100 tests Immunogen Human tonsillar B... more
CyFlow™ CD20 APC
HLDA WorkshopHLDA IV—WS Code B201
Quantity100 tests
ImmunogenHuman tonsillar B cells
SpecifityThe mouse monoclonal antibody 2H7 recognizes CD20 antigen, a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on pre-B lymphocytes, resting and activated B cells (not plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
Background InformationCD20 (B1, Bp35) is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Clark EA, Yokochi T: Human B Cell and B cell blast‑associated Surface Molecules defined with Monoclonal Antibodies. in:·Leucocyte·Typing·—·Bernard·A,·et·al.·(Eds). 1984; 339‑346.:339‑346. <·PMID:·Springer·68857-7_23·> | McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford·University·Press,·Oxford. 1987; 1‑1050. <·NLM·ID:·8913266·> | Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·> | Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·> | Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P: Association of 75/80‑kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20: Evidence against involvement of the cytoplasmic regions of CD20. J·Biol·Chem. 1995·Sep·22; 270(38):22632‑8. <·PMID:·7545683·> | Deans JP, Robbins SM, Polyak MJ, Savage JA: Rapid redistribution of CD20 to a low density detergent‑insoluble membrane compartment. J·Biol·Chem. 1998·Jan·2; 273(1):344‑8. <·PMID:·9417086·> | Polyak MJ, Deans JP: Alanine‑170 and proline‑172 are critical determinants for extracellular CD20 epitopes: heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002·May·1; 99(9):3256‑62. <·PMID:·11964291·> | Rose AL, Smith BE, Maloney DG: Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002·Sep·1; 100(5):1765‑73. <·PMID:·12176898·> | Polyak MJ, Ayer LM, Szczepek AJ, Deans JP: A cholesterol‑dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 2003·Jul; 17(7):1384‑9. <·PMID:·12835728·> | Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS: CD20‑induced lymphoma cell death is independent of both caspases and its redistribution into triton X‑100 insoluble membrane rafts. Cancer·Res. 2003·Sep·1; 63(17):5480‑9. <·PMID:·14500384·> | Diehl SA, Schmidlin H, Nagasawa M, van Haren SD, Kwakkenbos MJ, Yasuda E, Beaumont T, Scheeren FA, Spits H: STAT3‑mediated up‑regulation of BLIMP1 Is coordinated with BCL6 down‑regulation to control human plasma cell differentiation. J·Immunol. 2008·Apr·1; 180(7):4805‑15. <·PMID:·18354204·> | Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA: CD20‑directed small modular immunopharmaceutical, TRU‑015, depletes normal and malignant B cells. Clin·Cancer·Res. 2009·Apr·15; 15(8):2739‑46. <·PMID:·19351771·>

Article successfully added.